Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 224

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

Arts, Janine, King, Peter, Marin, Ann, Floren, Wim, Belin, Ann, Janssen, Lut, Pilatte, Isabelle, Roux, Bruno, Decrane, Laurence, Gilissen, Ron, Hickson, Ian, Vreys, Veronique, Cox, Eugene, Bol, Kees, Talloen, Willem, Goris, Ilse, Andries, Luc, Du Jardin, Marc, Janicot, Michel, Page, Martin, van Emelen, Kristof, Angibaud, Patrick · 2009 · Clinical Cancer Research

Abstract

Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clinical activity in the treatment of hematologic malignancies, but their activity in solid tumor indications has been limited. Most HDAC inhibitors in clinical development only transiently induce histone acetylation in tumor tissue. Here, we sought to identify a second-generation class I HDAC inhibitor with prolonged pharmacodynamic response in vivo, to assess whether this results in superior antitumoral efficacy. Experimental Design: To identify novel HDAC inhibitors with superior pharmacodynamic properties, we developed a preclinical in vivo tumor model, in which tumor cells have been engineered to express fluorescent protein dependent on HDAC1 inhibition, thereby allowing noninvasive real-time evaluation of the tumor response to HDAC inhibitors. Results: In vivo pharmacodynamic analysis of 140 potent pyrimidyl-hydroxamic acid analogues resulted in the identification of JNJ-26481585. Once daily oral administration of JNJ-26481585 induced continuous histone H3 acetylation. The prolonged pharmacodynamic response translated into complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma xenografts, whereas 5-fluorouracil was less active. JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity. Further characterization revealed that JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC50, 0.16 nmol/L). Conclusions: The potent antitumor activity as a single agent in preclinical models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising second-generation HDAC inhibitor. The compound is currently in clinical studies, to evaluate its potential applicability in a broad spectrum of both solid and hematologic malignancies. (Clin Cancer Res 2009;15(22):684151)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-0547

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 224

Metadata

Authors
Arts, J., King, P., Marin, A., Floren, W., Belin, A., Janssen, L., Pilatte, I., Roux, B., Decrane, L., Gilissen, R., Hickson, I., Vreys, V., Cox, E., Bol, K., Talloen, W., Goris, I., Andries, L., Du Jardin, M., Janicot, M., Page, M., van Emelen, K., & Angibaud, P.
Venue
Clinical Cancer Research
Published
2009-11-11
Volume
15
Issue
22
Pages
6841-6851
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2096165693
Cited by
224
References
5
FWCI
2.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-0547
The paper
Arts, J., King, P., Marin, A., Floren, W., Belin, A., Janssen, L., Pilatte, I., Roux, B., Decrane, L., Gilissen, R., Hickson, I., Vreys, V., Cox, E., Bol, K., Talloen, W., Goris, I., Andries, L., Du Jardin, M., Janicot, M., . . . Angibaud, P. (2009). JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-0547

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.